Status:
RECRUITING
To Evaluate the Clinical Efficacy of Probiotics in Patients with the Breast Cancer
Lead Sponsor:
GenMont Biotech Incorporation
Collaborating Sponsors:
Mackay Memorial Hospital
Conditions:
Breast Cancer
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. This study is designed to explore after consumption of probio...
Detailed Description
In 2020, the incidence rate of women's breast cancer in Taiwan was up to 82.1% . The death rate increased to 16%; in 2021, the ranking rose to no.3, and the death rate grew up to 24.6%. In the decades...
Eligibility Criteria
Inclusion
- Stage I-III breast patients using anthracycline-based and taxane-based chemotherapy (not limited before or after chemotherapy/surgery)
- BMI \> 18 kg/m\^2
- Age between 20 and 80 years old
- Patients judged by physicians to participate in this trial and who are willing
Exclusion
- Pregnant or lactating female patients
- Patients with bariatric surgery, gastrointestinal resections, Crohn's disease, celiac disease
- BMI \< 18 kg/m\^2
- Patient who have severe allergy to soybeans or peanuts
- Those who are under 20 years old or over 80 years old
Key Trial Info
Start Date :
April 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06039644
Start Date
April 8 2024
End Date
April 1 2026
Last Update
February 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mackay Memorial Hospital
Taipei, Taiwan